Stroke: Covidien battles "failed" clot-removing device study
February 8, 2013 by MassDevice staff
Medical device company Covidien releases 2-year study results combating a government-funded study that questioned the benefit of medical device intervention in stroke patient's future independence.
Medical device maker Covidien (NYSE:COV) touted 2-year study results demonstrating the safety and efficacy of its Solitaire FR revascularization system, combating another recently published study that questioned whether devices like Solitaire in provide long-term benefits to stroke patients.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
Navigation
NEWS
EuroPCR: Medtronic's renal denervation looks good in the real world
Medical device giant Medtronic unveils a 1st look from its global Symplicity renal denervation...
Stentys enrolls 1st patient in U.S. stent trial
Stentys launches a clinical trial aimed at backing a pre-market approval application with the FDA for...
Medtronic: We're about 2/3 through restructuring plan, layoffs
Medtronic is about 2/3 of the way through a restructuring plan involving 2,000 layoffs worldwide,...
Boston Scientific denies OrbusNeich accusations
Boston Scientific denies allegations by stents rival OrbusNeich that it tried to block the seizure of...
Breast cancer: Hologic wins FDA approval for new mammography software
Hologic wins FDA approval for its new C-View 2D imaging software for use with its 3D breast...
